• Press Release

"Mount Sinai Invests $200M into New Precision Medicine Data Science Program"

  • GenomeWeb
  • New York, NY
  • (November 01, 2018)

Icahn School of Medicine at Mount Sinai is investing $200 million into a new program to fast-track drug discoveries through the integration of large-scale data analysis and genomic technologies. The school also said it has recruited Adam Margolin, PhD, former director of computation biology at Oregon Health & Science University, to lead the initiative. Dr. Margolin, who will replace Eric Schadt at Mount Sinai, is a leader in the development of machine-learning algorithms to analyze large-scale datasets that predict which patients will respond to treatments. He has also developed software systems to enable collaborative analysis within national and international projects in cancer, genomics, cancer immunotherapy, stem cell research, and pediatric diseases. "We will bring together the top data scientists, genomic technology innovators, and disease experts who will work side by side every day to understand the molecular causes of complex diseases, rapidly test new therapies derived from these insights, and bring these therapies to patients faster than ever before,” said Dr. Margolin.

— Adam Margolin, PhD, Professor, Chair, Department of Genetics and Genomic Sciences, Senior Associate Dean, Precision Medicine, Director, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai

Learn more

Additional coverage:

Crain’s Health Pulse (Subscription required)
International Business Times
Star Tribune
Pittsburgh Post-Gazette
Investor Place
KFDA TV
The Buffalo News
Street Insider
KFMB TV
Health Data Management
DOT Med


About the Mount Sinai Health System

Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.

As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.

Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.